Company ProfilePremium

Gimv NV

Company Profile Analysis

Ticker: GIMV.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Gimv NV - Company showcase

Year Founded & Workforce

1980

95 Employees

Gimv NV logo

Gimv NV Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Gimv NV Overview

Gimv is Belgium's oldest and largest listed private equity company, an evergreen, balance-sheet investor that has spent more than 45 years buying, building and selling European mid-market businesses. Unlike closed-end fund managers, it invests its own permanent capital, which lets it hold companies longer and, since 2025, take long-horizon "Anchor" positions in larger champions such as Cegeka and Azelis alongside reference shareholder WorxInvest. Its sector-specialist teams operate four platforms — Consumer, Healthcare, Smart Industries and Sustainable Cities — across home markets in the Benelux, France and DACH. Following a EUR 247 mio rights issue in early 2025, Gimv is executing an explicit plan to double its portfolio, raised its annual portfolio-return target to 17.5%, and exited new life-sciences venture investing in January 2026. The portfolio reached a record EUR 2.4 billion in June 2026, yet the shares continue to trade at a material discount to NAV.


What Gimv does

Gimv acquires majority or significant minority equity stakes in privately held (and, via Anchor, selectively listed) European companies, works with management to accelerate growth — typically through organic expansion, buy-and-build acquisitions, internationalisation, professionalisation and, increasingly, digital transformation — and realises value via trade sales, secondary buyouts or IPOs. It is a principal investor: nearly all investments are made directly from its own balance sheet rather than through third-party funds. Historically Gimv also managed co-investment funds (e.g. Gimv-XL, final close EUR 609 mio) and earned management fees; this is now marginal (management fees from managed funds were EUR 78k in H1 2025 on the IFRS cash flow statement).

Company's own description (latest disclosures)

Gimv describes itself as a European investment company listed on Euronext Brussels with over 45 years of private equity experience, managing around EUR 2.5 billion of assets across some 60 companies. It positions itself as a recognised market leader in four sector-focused platforms (Consumer, Healthcare, Smart Industries, Sustainable Cities) plus Gimv Anchor Investments, partnering with entrepreneurial, innovative businesses with strong growth potential and supporting their transformation into market leaders. Each platform operates with a local team across its home markets of Benelux, France and DACH. Its long-standing tagline is "Building Leading Companies"; since FY2025 it has added a "Combining Intelligence" theme — combining entrepreneurial and human expertise with AI-enabled capabilities (H1 FY2026 press release).

Business and revenue model

Revenue/return driverDescriptionH1 FY2026 (EUR mio, Investment basis)FY2025 9m (EUR mio)
Unrealised gainsFair-value uplift, mainly driven by EBITDA growth at portfolio companies valued on multiples183.3155.8
Realised gainsCapital gains on exits above prior carrying value15.552.7
Interest incomeMainly capitalised interest on shareholder loansIncluded in portfolio result22.8
Dividend incomePortfolio dividends0.0Included
Portfolio resultSum of the above198.8231.4
Management/director fees and other operating incomeFees charged to portfolio companies and other2.5not separately verified

Gimv's model is therefore 100% "investment return" — there is no product, subscription or licensing revenue. Cash comes from exits, interest received and dividends; cash is consumed by new and follow-on investments, operating costs (personnel, long-term incentive plan payouts), interest on bonds, and shareholder dividends.

Value-chain position, customers and end-markets

Gimv sits at the capital-provider layer of the corporate value chain. Its "customers" are, in effect, (i) entrepreneurs, families and management teams seeking a growth partner, (ii) selling sponsors (e.g. Ambienta sold Groupe Cap Vert to Gimv in 2026), and (iii) ultimately the buyers of its exits (strategics such as CCL Industries, Ipsen, Impact Healthcare; other sponsors). Its own shareholders are its capital providers.

End-markets served (through portfolio companies): consumer brands and food (juvenile products, hearing protection, spices, food-safety software, e-learning); healthcare services and medtech (outpatient and home care, oncology centres, equine care, spinal implants, CDMOs); industrial technology (electronics/mechatronics, communication systems, sports-surface machinery); and sustainable-cities services (energy and water network contracting, technical installations, energy renovation, tree and vegetation management, temporary energy rental); plus IT services (Cegeka) and specialty chemical distribution (Azelis) via Anchor.

Independent characterisation

Analytically, Gimv is best understood as a permanent-capital, mid-market buyout and growth investor with a recent pivot toward larger, longer-hold "core-plus" positions. Three features differentiate it from European peers: (1) its sector-platform organisation (rather than generalist deal teams); (2) its Benelux/France/DACH regional focus with physical offices in Antwerp, The Hague, Paris and Munich; and (3) since 2024, the presence of an entrepreneurial reference shareholder (WorxInvest, controlled by the Dierckx family vehicle structure; Executive Chairman Filip Dierckx is Gimv's Chairman) that co-invests in Anchor and Infravest. The 2025 recapitalisation, the step-change in investment pace (EUR 466 mio in 9 months) and the January 2026 exit from new life-sciences venture investing mark a shift from a diversified "Flemish development company" heritage toward a scaled, return-target-driven European private equity compounder.

Strategy

Stated strategy (themes from FY2024-25 / FY2025 reporting and investor communications)

  1. "Building Leading Companies" — long-standing mission: partner with entrepreneurial, innovative businesses and transform them into market leaders.

  2. Accelerated growth — "double the portfolio" — ambition announced in late 2024 and funded by the February 2025 rights issue. By June 2026 the portfolio was EUR 2.4 bn (≈+50% vs. the capital-increase moment), and above EUR 2.5 bn including Cap Vert.

  3. Higher return target — annual portfolio return target raised from 15% to at least 17.5%.

  4. Longer investment horizon and Anchor — "anchoring" companies with strong long-term growth potential via Gimv Anchor (with WorxInvest), aiming for sustained compounding value. Anchor portfolio is reported to be "ahead of schedule".

  5. More efficient capital structure — use of debt at Gimv level (bonds, RCF doubled to EUR 400 mio) so equity is fully invested.

  6. Sector focus — concentrate on four platforms plus Anchor; discontinued new Life Sciences investments (January 2026) to focus capital on sectors benefiting from digital transition.

  7. "Combining Intelligence" / digital transformation — AI-augmented human expertise to help portfolio companies accelerate digital transformation; new ExCo-level Chief Digital Transformation role (September 2026).

  8. Sustainability as value creation — first platform-specific sustainability value-creation blueprint (H1 2026); company-specific decarbonisation support.

  9. Dividend policy — not to lower the dividend except in exceptional circumstances, and to increase it whenever sustainably possible.

Initiative register (last 24 months)

DateInitiativeTypeTargets / detail
Nov 2024Accelerated growth strategyStrategic planDouble portfolio; 17.5% return target; leverage
2,024InfravestVehicle/partnershipWith Belfius (20%) and WorxInvest (40%)
Jan–Feb 2025EUR 247 mio rights issueCapitalNet EUR 243 mio
Feb 2025Gimv Anchor Investments JVNew business line75% Gimv / 25% WorxInvest; Cegeka first holding
Mar 2025Head of Anchor appointedOrganisationBart Troubleyn
2,025Calendar-year reportingGovernance/reportingFY2025 shortened to 9 months
Jan 2026Exit new Life Sciences investingPortfolio strategy11 companies (≈5% of portfolio) run off
Q1 2026RCF doubled to EUR 400 mioFinancingStrengthens investment capacity
Apr 2026Azelis stakeAnchor investment5% → >6%
Jun 2026Cap VertPlatform investmentTop-10 holding
H1 2026Sustainability value-creation blueprintESGFirst platform-specific blueprint
Sep 2026Chief Digital Transformation roleOrganisationExternal international hire, name TBA
OngoingGimv Climate PlanESG70% own Scope 1 & 2 reduction target; >50% achieved

Medium-term targets / guidance

TargetValueStatus
Annual portfolio return≥17.5% (long-term objective; previously 15%; earlier long-term objective shown as 12%)18.8% annualised in H1 FY2026
Portfolio sizeDouble (from ≈EUR 1.6 bn at the capital increase)EUR 2.4 bn (Jun 2026); >EUR 2.5 bn with Cap Vert
DividendNot lowered; increase when sustainableEUR 2.60 annual rate maintained (EUR 1.95 for 9m)
Earnings/NAV guidanceNot provided (no explicit EPS or NAV guidance)—

Products & Services

For an investment company, the "product catalog" is (a) its investment offerings to entrepreneurs, and (b) the portfolio holdings. Each holding is listed with what is publicly verifiable. Entry stake sizes and valuations per company are not publicly disclosed unless stated.

Gimv's "offerings" (investment products)

OfferingDescriptionTypical counterpartyPricing/terms
Majority buyoutsControl acquisitions, often with management reinvestment, as platform for buy-and-buildFounders, families, selling sponsors—
Significant minority growth equityMinority stakes with governance rights to fund expansionEntrepreneurial firms—
Continuation / reinvestmentRe-investment alongside new owners or in combined entities (e.g. Bugaboo-Joolz, Liveo/Medi-Markt)Existing holdings—
Anchor investmentsLong-term, larger-ticket stakes in European champions, private or listed, co-invested 75/25 with WorxInvestCegeka, Azelis—
Venture capital (Life Sciences)Discontinued for new deals since Jan 2026; follow-ons in existing companies onlyBiotech/medtechNot applicable

Gimv Anchor Investments

HoldingCountryActivityEntryKey facts
CegekaBelgiumIndependent European ICT services provider2025 (Anchor); Gimv historically a shareholderRevenue ≈EUR 1.3 bn in 2025 (stable); "year of transition" with restructuring of prior acquisitions; three new board members; new CEO Koen Deryckere (ex-CEO & President France & Benelux at a large IT services group, per AGM 2026 deck). Largest single Gimv holding category per FY2025 top-5 table
Azelis Group NVBelgium (BEL 20)Specialty chemicals and food ingredients distribution30 Apr 20265% at announcement, >6% by 30 June 2026; Gimv Anchor expects to be a top-five shareholder; led by Bart Troubleyn and Floris van Halder

Anchor portfolio total: ≈EUR 375 mio, ≈15% of total Gimv portfolio (Gimv H1 2026 results day presentation), of which 75% is funded from Gimv's balance sheet. Note: this figure appears to be on a 100% basis or to include WorxInvest's share; Gimv's own Anchor line was EUR 277 mio at 30 June 2026.

Healthcare platform

HoldingCountryActivityEntryNotes
SpineartSwitzerlandMedtech: implants and technologies for spine surgery2025 (as top-5 holding; long-standing investor)CHF 25 mio capital increase (Sep 2025) with EGS Beteiligungen; ≈EUR 140 mio 2025E revenue, 16% average growth over 5 years; >360 employees; BAGUERA® C cervical disc received FDA approval for 1- and 2-level use (Aug 2026); Spinem Robotics partnership (EUR 10 mio, Apr 2024)
Liveo Gruppe (from Medi-Markt)GermanyIncontinence care at home2025 (continuation investment)Top-10 holding
Equine Care GroupBelgiumHigh-quality equine medical care: clinics, ambulatory care, reproduction, supplements, lab2,025Top-10 holding; CNP joined to accelerate global expansion (Nov 2025); bolt-ons in H1 2026
NovicareNetherlandsB2B specialised medical care services in elderly and disability care2025 (Aug)—
ILC (iLC)FranceLeading private group of cancer treatment centres2,025Top-20 holding
BioConnectionNetherlandsCDMO for injectable (bio)pharmaceuticals2,022Top-20; manufacturing capacity expansion in H1 2026; 100% renewable electricity
Awelando Gruppe (attribution probable)GermanyOutpatient care in assisted living facilities and day care2,025Named in Gimv portfolio filter; description matches FY2025 new-investment slide
MVZ HoldingSwitzerlandGroup of medical practices—Sold Aug 2026, no NAV impact
AlpenBlu Clinics (formerly Les Psy Réunis)SwitzerlandOutpatient mental healthcare—Sold to Impact Healthcare, 30 Jun 2026
Other names in portfolio filter—Benedenti (dental group practices, BE), Equipe Zorgbedrijven (NL), Curana, Ambulantis, Excellent Clinics, SGH Medical Pharma, rehaneo—Some may be exited

Consumer platform

HoldingCountryActivityEntryNotes
Alpine (attribution probable)NetherlandsPassive consumer hearing protection2,025Top-5 holding in FY2025 table ("perfect sound, carefree enjoyment")
Bugaboo Group (Bugaboo-Joolz)NetherlandsPremium strollers and adjacent juvenile products2025 reinvestment (Joolz held since 2016)Gimv sold Joolz into the combination and reinvested (Jul 2025); top-20
The Spice FactoryBelgiumLeading Belgian herbs and spices manufacturer2025 (FY2024-25)Top-15; sustainability roadmap
Quality GuardBelgiumFood safety compliance software/solutionsNov 2025Platform for European buy-and-build; acquisitions in H1 2026
sofatutorGermanyOnline learning platform2,021Top-15; acquired SchoolMouv (Q1 2026)
Other names in portfolio filter—Babyshop Group, Blendwell Food Group, The Wallfashion House (acquired control of Rasch, Apr 2024), Legallais (FR ironmongery distribution), United Dutch Breweries, Olyn, Wolf Lingerie, Hecht——

Smart Industries platform

HoldingCountryActivityEntryNotes
TelevicBelgiumHigh-tech, high-quality communication systems2,020Top-5 holding; Televic Healthcare Solutions sold to Esprit ICT (Jul 2025)
Metis GroupNetherlandsDeveloper/manufacturer of electronic and mechatronic products and systems (formed by AME and Variass)2,022Top-10; A1 Electronics joined (Mar 2024); agreement to acquire majority of EPAC (Aug 2026)
SMG SportplatzmaschinenbauGermanyMachinery for installing and maintaining synthetic sports surfaces2,024Top-15
German electrical engineering holdingGermanyEnd-to-end electrical engineering solutions2,021Top-15
ALT TechnologiesNetherlands——Majority stake sold to CCL Industries (Jan 2026)
Other names in portfolio filter—Projective Group, WDM-Deutenberg Group, Laser 2000, Kind Technologies, Köberl, Witec, RoboJob, Castelein Sealants, Arplas Systems, OTN Systems, Smart Battery Solutions——

Sustainable Cities platform

HoldingCountryActivityEntryNotes
Groupe Cap VertFranceFrance's leading multi-specialist tree and vegetation critical-management servicesSigned 25 Jun 2026; closing expected Sep 2026≈EUR 180 mio revenue; >1,200 staff; ≈60 branches; >18 acquisitions since Dec 2021 under Ambienta; to be a top-10 Gimv holding; CEO Eric Girot
HeminkNetherlandsB2B energy-renovation and maintenance specialist for sustainable real estateJul 2025Top-20; bolt-ons in H1 2026
Fronnt (attribution probable)BelgiumOne-stop shop for technical installations, products and services2,022Top-15; Intec group, Van Severen and Famil joined (Aug 2025)
Dutch network contractorNetherlandsSpecialist contractor in cable and pipeline networks for energy and water2,021Top-5 holding
French fencing groupFranceProduction of gates and fencing and fencing solutions2,022Top-10
French temporary-energy rental group (Tibbloc, attribution probable)FranceRental of ready-to-use temporary energy solutions2,024Top-10
German pipeline/civil engineering groupGermanyPipeline construction, cable laying, specialised civil engineering2,022Top-20
ItinerisBelgiumUtilities software2,013Exited in FY2025
Other names in portfolio filter—Itho Daalderop & Klimaatgarant (NL), Brakel (natural climate control/fire safety), Well Services Group, Acertys Group, Alro Group, E.GRUPPE, Techinfra, GPNZ, Coolworld Rentals——

Life Sciences (run-off: 10 companies at 30 June 2026)

HoldingActivityLatest verified milestone
Exciva (Germany)Clinical management of neuropsychiatric symptoms in Alzheimer's diseaseGimv co-led EUR 51 mio Series B with EQT Life Sciences (Jan 2026)
Kinaset TherapeuticsInhaled therapies for respiratory diseaseUSD 103 mio Series B (Jan 2026)
Mediar TherapeuticsFirst-in-class fibrosis portfolioUSD 76 mio Series B (Jan 2026)
Complement TherapeuticsCTx001 for geographic atrophy secondary to AMDFDA IND clearance (Oct 2025); FDA Fast Track (Jan 2026)
Kivu BioscienceKIVU-107 PTK7-targeting ADCFirst patient dosed Phase 1 (Jan 2026)
ImmunOs TherapeuticsImmuno-oncologyNew CEO (Jan 2026)
Topas TherapeuticsImmune tolerance; celiac diseasePhase 2 readout late 2024
Biotalys (listed)Protein-based biocontrolUS EPA approval for EVOCA (Dec 2025)
Onera HealthSleep diagnosticsGimv co-led EUR 30 mio Series C
ImCheck TherapeuticsImmuno-oncologyExited: sold to Ipsen (Oct 2025)

Infra & other

HoldingDescription
InfravestVehicle with Belfius (20%) and WorxInvest (40%); Gimv sold 50% of its stake to WorxInvest in FY2024-25. Holds stakes in listed TINC (Gimv participated in TINC's rights issue in FY2025) and unlisted DG Infra Yield. ≈4% of portfolio
3F / otherLegacy fund-of-funds positions; ≈1% of portfolio at Dec 2025

Concentration

  • Five largest investments: EUR 635 mio, ≈30% of portfolio (Dec 2025).

  • Ten largest: EUR 1,016 mio at Dec 2025; 50.3% of total at June 2026.

  • Twenty largest: EUR 1,476 mio, ≈70% of portfolio (Dec 2025).

  • No single investment >10% of portfolio value (June 2026).

  • Vintage profile (Dec 2025): 38% invested 2024 or later; 34% 2021–2023; 14% 2018–2020; 13% 2016–2017; 1% 2015 or earlier — a young portfolio that implies exits are weighted to 2027+.

  • Valuation method (Dec 2025): multiples 60%; price of last round 37%; listed 1%; other 2%.

Financial Narrative

Source for annual figures: Gimv "Key financial information" (consolidated, IFRS), FY2023-24 and FY2024-25 results releases, FY2025 deck. FY2025 = 9 months.

Income statement analogue

Notes: (a) In this table FY2025A = FY2024-25 (12 months) and FY2025B = shortened FY2025 (9 months). (b) Diluted EPS is not separately disclosed; no material dilutive instruments were identified (LTIP is cash-settled). (c) Gross profit, operating income in an industrial sense, EBITDA and associated margins are N/M for an investment company. (d) A third-party profile (Beursgenoten) cites FY2024-25 "revenue" of EUR 300.2 mio, consistent with the implied portfolio result above. (e) FY2025 dividend of EUR 1.95 is the EUR 2.60 annual rate pro-rated for 9 months.

Net profit "margin" analogue (net profit / portfolio result): FY2022 ≈69%; FY2023 N/M; FY2024 ≈75%; FY2025A ≈73%; FY2025B ≈75%. The gap reflects operating costs, the LTIP (Gimv's carried-interest equivalent for staff), finance costs and minority interests.

Cost structure (H1 FY2026, Investment basis): services and other goods EUR 7.8 mio; remuneration EUR 14.9 mio; LTIP benefits EUR 12.1 mio; depreciation EUR 1.4 mio; other operating expenses EUR 4.8 mio — total ≈EUR 41 mio for six months, or ≈EUR 82 mio annualised, ≈3.9% of NAV annualised (including LTIP) or ≈3.3% excluding LTIP. Finance costs EUR 5.3 mio; finance income EUR 2.4 mio; tax EUR 0.9 mio.

Commentary: Gimv's earnings are volatile and multiple-driven at the extremes (FY2019-20 and FY2022-23 losses), but over the past three full periods have been driven chiefly by EBITDA growth at portfolio companies: in H1 FY2026 EBITDA growth alone contributed EUR 196.3 mio of the EUR 198.8 mio portfolio result, while multiples were stable at 9.7x. Gimv has beaten its return target in each of the last four reporting periods (19.1%, 19.3%, 19.1% annualised, 18.8% annualised), and in eight of the ten years to 2024 had exceeded its then 15% target (KBC Securities).

Interim trend (calendar-year basis)

H1 2025 is restated to January–June 2025. Note: Simply Wall St reports H1 2026 EPS of EUR 3.40 vs EUR 5.15 — this conflicts with the company's EUR 4.0 vs EUR 2.3 and appears to reflect a mismatched period mapping after the fiscal-year change; company figures are used.

Balance sheet

Notes: FY2025B cash of EUR 323.7 mio comprises EUR 173.2 mio cash and EUR 150.5 mio marketable securities (Investment basis). At 30 June 2026 bonds on balance sheet were EUR 275.0 mio non-current plus EUR 83.8 mio current (current includes the EUR 75 mio tranche repaid 5 July 2026, plus accrued items). Goodwill and intangibles are negligible (intangibles EUR 0.3 mio). Working capital is N/M; current assets EUR 137.0 mio vs current liabilities EUR 94.5 mio at 30 June 2026.

Leverage and liquidity at 30 June 2026:

Gimv states its equity is now "more than fully invested" in the portfolio — a deliberate move from a structurally net-cash position (EUR 668.8 mio liquidity at March 2025) to modest net debt, consistent with the November 2024 strategy to use leverage more efficiently.

Cash flow analogue

FY2025A divestments include the sale to WorxInvest of 25% of Gimv's Anchor (Cegeka) stake and 50% of its Infravest stake. Optional (scrip) dividends reduce cash outflow (e.g. 64.2% of FY2024-25 dividend rights taken in shares, EUR 41.8 mio reinvested). Capex is N/M (PP&E purchases EUR 0.2 mio in H1 2026). Buybacks: own-share purchases EUR 3.5 mio and sales EUR 2.6 mio in H1 2026 (linked to staff share-purchase plan; a buyback was completed 4 March 2025 for this purpose). Operating cash flow on Investment basis in H1 2026 was EUR -121.1 mio, because investments are classified within operating activities for an investment entity; free cash flow is therefore N/M.

Ratios

Notes: (a) Gimv's table shows "+19.0%" for 31 Dec 2025, but price EUR 44.65 vs NAV EUR 55.1 is a 19.0% discount; the sign appears to be a presentation error and is corrected here. (b) ROIC, net debt/EBITDA, interest coverage on EBITDA, asset turnover and cash conversion cycle are N/M. (c) Debt/equity at 30 June 2026 ≈ 0.17x (EUR 350 mio bonds / EUR 2,105 mio equity), falling to ≈0.13x after the July 2026 repayment. (d) Interest cover analogue: H1 2026 profit before financing EUR 162.8 mio vs finance costs EUR 5.3 mio ≈ 31x.

Growth metrics

Key analytical point: NAV per share has compounded far more slowly than the portfolio because (i) Gimv distributes roughly a third or more of profits as dividends, (ii) the February 2025 rights issue was priced at EUR 34.50 — about 35–38% below the prevailing NAV — mechanically diluting NAV/share (NAV/share was EUR 55.6 at Sep 2024 and EUR 53.3 at Mar 2025 "after the impact of the capital increase"), and (iii) LTIP and running costs absorb roughly 3–4% of NAV annually.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentStatus

Consumer (CO)

Consumer-facing brands, food, education, consumer services

Core platform

Healthcare (HC)

Care services, medtech, healthcare products and services (renamed from "Health & Care")

Core platform

Smart Industries (SI)

Industrial technology, electronics, automation, B2B tech services

Core platform; head departing (Sep 2026)

Sustainable Cities (SC)

Infrastructure services, energy transition, utilities, building technology

Core platform

Gimv Anchor Investments

Long-term (minority or significant) stakes in larger European champions; JV 75% Gimv / 25% WorxInvest

Core since Feb 2025

Life Sciences (LS)

Venture investments in pre-revenue, R&D-driven biotech/medtech

Run-off (no new investments since 26 Jan 2026)

Infra & other (Infravest, 3F, other)

Infravest (with Belfius and WorxInvest) holding TINC and DG Infra Yield stakes; legacy fund-of-funds ("3F")

Non-core / financial

Revenue by Segment (EUR)

Segment (EUR mio)Dec2025Jun2026

Consumer

369412

Healthcare

503504

Smart Industries

454507

Sustainable Cities

418480

Anchor

165277

Life Sciences

109112

Infra and other

103115

Total portfolio

2,1212,407

Segment share of portfolio (%)

Segment share of portfolio (%)Dec2025Jun2026

Consumer

1717

Healthcare

2421

Smart Industries

2121

Sustainable Cities

2020

Anchor

812

Life Sciences

55

Infra and other

55

Segment Overview — Consumer

SegmentRealised result (EUR mio)Unrealised result (EUR mio)Interest income (EUR mio)Portfolio result (EUR mio)Portfolio return (%) 9m

Consumer

4.31.57.713.64.8

Healthcare

0.048.33.151.318.8

Life Sciences

17.4-21.00.6-3.0-2.2

Smart Industries

-3.653.26.756.314.7

Sustainable Cities

32.767.04.4104.131.5

Anchor

0.00.00.00.00.0

Infra & 3F

1.96.70.49.116.8

Total

52.7

155.8

22.8

231.4

14.3

Segment Margins & Growth (%)

Metric (like-for-like, portfolio companies)FY2025 (calendar 2025, latest estimates)H1 2026 YTD vs prior year

Sales growth, core platforms

≈10–11%

8%

EBITDA growth, core platforms

≈15%

12%

Share of growth that is organic

≈2/3 (EBITDA)

≈2/3 (sales and EBITDA)

Platforms with EBITDA growth >20%

Healthcare, Sustainable Cities

—

Weighted average EV/EBITDA used

9.7x (after -17% calibration)

9.7x (after -16% calibration)

Average portfolio leverage (net senior financial debt/EBITDA)

1.8x (48 companies)

—

Companies with leverage >4x

9 (<5% of portfolio value)

—

“—” = not publicly disclosed.

Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025AFY2025B

Period label

Apr21–Mar22

Apr22–Mar23

Apr23–Mar24

Apr24–Mar25

Apr25–Dec25 (9m)

Metric

FY2022

FY2023

FY2024

FY2025A

FY2025B

Portfolio result EUR mio (FY22–FY25A implied)

251.5-1.4290.9300.9231.4

Gross portfolio return %

20.4-0.119.119.314.3

Net profit EUR mio

174.3-59.5217.1219.0173.3

Net return on equity %

13.7-4.216.514.79.0

EPS EUR (basic)

6.59-2.207.797.474.80

Gross dividend per share EUR

2.602.602.602.601.95

Payout ratio %

37.4—32.633.141.4

Total gross dividend EUR mio

65.169.370.872.571.8

Financial Analysis

MetricH12025H12026

Portfolio result EUR mio

119.6198.8

Portfolio return % (non-annualised)

6.79.4

Net result EUR mio

85.8148.4

Net return % (non-annualised)

5.27.5

Net result per share EUR

2.34.0

Investments EUR mio

226.4134.0

Exit proceeds EUR mio

369.742.0

Balance Sheet (EUR) and Per-Share Data

Metric (EUR mio, IFRS unless noted)FY2022FY2023FY2024FY2025AFY2025BH12026

Total assets

1,840.61,728.51,917.22,365.02,456.42,541.3

Portfolio (Investment basis)

1,448.51,522.91,559.01,623.32,120.92,407.3

Cash and equivalents (incl. marketable securities where noted)

377.8194.4346.8668.8323.7131.4

Equity (group share)

1,413.01,312.41,489.31,906.82,029.52,105.1

NAV per share EUR

53.048.253.453.355.157.2

Total liabilities (computed: assets − equity)

427.6416.1427.9458.3426.9436.2

Bonds outstanding, principal

————350350

Shares outstanding mio

26.6527.2227.8735.7736.8136.81

Financial Analysis — Cash on balance sheet

ItemEUR mio

Cash on balance sheet

131.4

Undrawn revolving credit facility (doubled in Q1 2026)

400.0

Total available liquidity

531.4

Bonds outstanding

350.0

Net cash (company-reported)

-216.0

Bonds after 5 Jul 2026 repayment

275.0

Available liquidity after repayment

456.4

Long-term incentive plan (LTIP) liabilities

57.7

Lease liabilities

9.5

Dividends & Capital Returns (EUR)

Metric (EUR mio)FY2022FY2023FY2024FY2025AFY2025B

Investments (own balance sheet)

193.8260.6115.8336.1466.4

Divestments (own balance sheet)

218.9175.0364.6560.0196.5

Net investment (investments − divestments)

-25.185.6-248.8-223.9269.9

Gross dividend declared for the year

65.169.370.872.571.8

Returns & Leverage Ratios (%) — ROE %

RatioFY2022FY2023FY2024FY2025AFY2025B

ROE % (reported net return on equity)

13.7-4.216.514.79.0

ROA % (net profit / year-end total assets, calc.)

9.5-3.411.39.37.1

Equity / total assets % (calc.)

76.875.977.780.682.6

Premium (+) / discount (−) to NAV % (company-reported)

3.0-7.7-16.7-26.1-19.0

Share price at FY close EUR

54.6044.5044.5039.4044.65

Valuation Snapshot

MetricValueBasis

Portfolio CAGR, Mar 2021 (EUR 1,233 mio) → Jun 2026 (EUR 2,407 mio)

≈13.5% p.a.

Company-reported

Portfolio growth since early-2025 capital increase

≈+50%

Company-reported

Equity growth, Mar 2021 (EUR 1,274 mio) → Jun 2026 (EUR 2,105 mio)

≈+65%

Calc. (boosted by EUR 243 mio net rights issue and scrip dividends)

NAV/share, Mar 2021 (EUR 49.0) → Jun 2026 (EUR 57.2)

≈+17%, plus ≈EUR 13.5 cumulative gross dividends

Calc.

Implied portfolio-result CAGR

N/M (FY2023 negative base)

—

Last verified close

EUR 44.45 (28 Aug 2026)

Investing.com

52-week range

EUR 41.80 – 50.10

Investing.com

1-year price change (to Aug 2026)

≈+5.9%

Investing.com

3-year price change (31 Mar 2023 EUR 44.50 → EUR 44.45)

≈0% (calc.)

Gimv; Investing.com

5-year price change (31 Mar 2021 EUR 51.00 → EUR 44.45)

≈−12.8% (calc.)

Gimv; Investing.com

Dividends received over 5 years (FY2021-22 to FY2025, gross)

EUR 12.35 per share

Gimv

All-time high / low

EUR 57.65 (21 Feb 2020) / EUR 14.30 (10 Oct 2002)

TradingView

Average daily volume

≈20,000 shares

Investing.com

Liquidity providers

KBC Securities; Bank Degroof Petercam

Gimv

Region Overview

RegionShare of portfolio %Implied value EUR mio (calc. on 2,121)

Belgium

32679

DACH (Germany, Austria, Switzerland)

27573

Netherlands

24509

France

14297

Rest of world

364

Region share of portfolio (%)

Region share of portfolio (%)Dec2025

Belgium

32

DACH

27

Netherlands

24

France

14

Rest of world

3

Platform Details

PlatformBelgiumNetherlandsFranceDACH

Anchor

Cegeka

———

Healthcare

Equine Care Group

BioConnection, Novicare

ILC

Spineart (CH), Liveo (DE)

Consumer

The Spice Factory, Quality Guard

Alpine, Bugaboo Group

—

sofatutor (DE)

Smart Industries

Televic

Metis Group

—

SMG (DE), electrical engineering (DE)

Sustainable Cities

Fronnt

Network contractor, Hemink

Fencing group, temporary energy rental; Cap Vert (2026)

Pipeline/civil engineering (DE)

Capital Markets

MetricFY2021FY2022FY2023FY2024FY2025AFY2025B

Share price EUR (FY close)

51.0054.6044.5044.5039.4044.65

NAV per share EUR

49.053.048.253.453.355.1

Premium/discount to NAV %

4.13.0-7.7-16.7-26.1-19.0

Valuation Snapshot by Multiple

MultipleValueBasis

Price / NAV

≈0.78x

EUR 44.45 / EUR 57.2 (Jun 2026)

Discount to NAV

≈22%

Calc.

P/E (TTM)

≈7.0x

EUR 44.45 / TTM EPS EUR 6.35 (Investing.com)

Dividend yield

≈5.8% on EUR 2.60 run-rate; company stated 5.2% annualised on 26 May 2026 close

Calc.; Gimv

EV/EBITDA, EV/Sales

N/M (investment company)

—

P/B

Same as P/NAV

—

Capital Markets — Number of covering analysts

ItemValueSource

Number of covering analysts

6

Simply Wall St; TradingView

Average 12-month target

EUR 51.25

Investing.com

High / low target

EUR 56 / EUR 42

Investing.com; TradingView

Implied upside vs EUR 44.45

≈+15%

Calc.

Named coverage

KBC Securities (Livio Luyten) — positive tone, previously "accumulate/buy" on resumption after the capital increase

Bolero

Capital Markets (FY2017–FY2025B)

MetricFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025AFY2025B

Gross DPS EUR

2.502.502.502.502.502.602.602.602.601.95

Capital Markets — Moody's / S&P / Fitch

ItemDetail

Moody's / S&P / Fitch

No public credit rating identified — Gimv appears to be unrated

Bonds

EUR 350 mio outstanding at 30 Jun 2026; EUR 75 mio tranche matured/repaid 5 Jul 2026; EUR 275 mio outstanding thereafter.

Revolving credit facility

EUR 400 mio, undrawn at 30 Jun 2026; renegotiated and doubled with Belgian banks in Q1 2026; maturity not disclosed in reviewed sources

Net cash

−EUR 216 mio at 30 Jun 2026 (company-reported)

Analyst Conclusions

Management guidance and consensus

Gimv does not give earnings or NAV guidance. Its standing targets are a portfolio return of at least 17.5% per year, doubling the portfolio, and a non-declining dividend. Management expressed "strong confidence in continued above-market growth performance" based on portfolio companies' 2026 budgets (FY2025 deck), and in September 2026 reported that market multiples since 30 June had not indicated any need for valuation adjustment.

Bull case

  1. Compounding at ≈15% NAV growth plus a ≈5–6% yield: H1 2026 NAV/share grew 7.5% (15% annualised) after paying a EUR 1.95 dividend; if sustained, the current ≈22% discount implies material upside even without a re-rating.

  2. Deployment is largely done, liquidity remains: with the portfolio near EUR 2.5 bn including Cap Vert and EUR 456 mio of liquidity, Gimv can harvest growth from a young, recently-bought portfolio while retaining dry powder.

  3. Identifiable catalysts: Spineart's FDA approval, Cegeka's new-CEO turnaround, Azelis' cyclical recovery, Cap Vert's buy-and-build and industrial recovery for Smart Industries.

Bear case

  1. Structural discount: the discount widened from +3% (Mar 2022) to −26% (Mar 2025) despite record profits, suggesting the market applies a durable haircut for unlisted marks, costs/LTIP and a controlling shareholder.

  2. Anchor concentration and minority positions: Cegeka's flat 2025 and Azelis' cyclicality put a large, growing share of NAV (≈12% Gimv share; ≈15% on a 100% basis) into big single names with limited control or exit flexibility.

  3. Shift to net debt and back-ended exits: net cash turned to −EUR 216 mio, exits slowed to EUR 42 mio in H1 2026, and 38% of the portfolio is 2024+ vintage — a downturn could pressure marks before realisations validate them.

Key catalysts and monitorables (next 12 months)

ItemTimingWhat to watch
Cap Vert closingSep–Q4 2026Completion, entry multiple disclosure (if any), first bolt-ons
New Head of Smart Industries; CDTO introductionH2 2026Team continuity
FY2026 annual results18 Feb 2027Full-year portfolio return vs 17.5%; NAV/share; exits; Anchor marks
FY2026 dividend proposalFeb–May 2027Return to EUR 2.60 full-year rate or increase
Cegeka 2026 performance2026–27Revenue/margin recovery under new CEO
Spineart US commercial ramp2026–27Valuation uplift
Exit activityOngoingRealisations at or above carrying value
WorxInvest stakeOngoingFurther creeping increases; governance
Valuation multiples / calibrationEach reporting date9.7x average multiple; calibration factor
Energy prices / macroOngoingPortfolio-company margins

Concluding analyst verdict

Gimv enters late 2026 in the strongest operational shape of its recent history. The 2025 recapitalisation has been deployed quickly — EUR 466 mio in nine months, then Azelis and Cap Vert in 2026 — and the portfolio has grown to a record EUR 2.4 billion, above EUR 2.5 billion pro forma. More importantly, the quality of returns is high: H1 2026's EUR 199 mio portfolio result came almost entirely from EBITDA growth at portfolio companies, with multiples flat at 9.7x and look-through leverage a moderate 1.8x. Four consecutive reporting periods above the raised 17.5% target suggest the return ambition is credible rather than aspirational.

The equity story, however, has not kept pace. NAV per share has risen only modestly over five years once dividends and the dilutive EUR 34.50 rights issue are accounted for, and the shares still trade roughly 22% below the June NAV of EUR 57.2. The market appears to discount three things: the opacity of unlisted marks, the cost and LTIP drag (roughly 3–4% of NAV annually), and governance considerations around a 37% reference shareholder that is also a co-investor and buyer of Gimv assets. The Anchor strategy amplifies both upside and concentration; Cegeka's flat 2025 is a reminder that large holdings can stall.

The investment case hinges on Gimv converting a young portfolio into realised exits at or above book over 2027–2028, which would validate its marks and is the most plausible path to narrowing the discount. Key watch-points are exit pace, Anchor performance, team stability after the Smart Industries departure, and any further shift in WorxInvest's role.


All figures EUR; FY2025 is a 9-month period.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / notesPrior roles / educationBirth year

Koen Dejonckheere

CEO and executive director

CEO since Oct 2008 (one aggregator says 2015 — discrepancy)

MBA, M.Sc., engineering degree (Simply Wall St); joined Gimv 1998 per Altss

1969

Kristof Vande Capelle

CFO (acting via a management company)

Long-standing CFO; co-signs management declarations

—1969

Edmond Bastijns

Chief Legal Officer & Secretary General

——1973

Bart Diels

Managing Partner & Head of Healthcare

——1969

Bart Troubleyn

Managing Partner & Head of Gimv Anchor

Since March 2025

Former CEO/COO with international, M&A, restructuring and IT/digital transformation experience

—

Tom Van de Voorde

Platform Head, Smart Industries

19 years at Gimv; leaving (announced 3 Sep 2026); successor to be announced

——

Erik Mampaey

—

Listed by Beursgenoten

——

Koen Bouckaert

—

Listed by Beursgenoten

——

Bram Vanparys

—

Listed by Beursgenoten

——

New Chief Digital Transformation officer

Newly created ExCo role (Sep 2026)

Filled by "an external international profile"; name to be announced

——

“—” = not publicly disclosed.

Board of Directors

DirectorRoleNotes

Filip Dierckx

Chairman (since 21 May 2024); chair of remuneration committee

Executive Chairman of WorxInvest; non-independent

Koen Dejonckheere

CEO, executive director

Non-independent

Robert van Goethem

Director (co-opted May 2024 on WorxInvest recommendation)

Non-independent (shareholder representative)

Marc Valentiny

Director (co-opted May 2024 on WorxInvest recommendation)

Non-independent (shareholder representative)

Luc Missorten

Director

—

Brigitte Boone

Director

Born 1960

Hilde Windels

Director

Born 1966

Johan Deschuyffeleer

Director

Born 1958

Manon Janssen

Director

Born 1961

Frank Verhaegen

Director

Born 1960

An Vermeersch

Director

Born 1971

Major Shareholders

HolderShares% of voting rightsDate / source

WorxInvest NV

13,672,01637.14

Current, Gimv shareholder structure page (after scrip dividends, rights issue and market purchases)

WorxInvest NV — prior notifications

—

28.73 → 32.32 → 35.44

21 May 2024 / 11 Feb 2025 / 30 Jul 2025

Norges Bank

—2.90

Last notification 8 Jan 2018 (below 3% threshold; current holding not disclosed)

Free float

23,138,91762.86

Computed

Competitive Landscape

Key Competitors

CompetitorTypeArenaRelative positioning vs Gimv

Ackermans & van Haaren (BE, listed)

Diversified holding

Capital and some deals

Larger, more diversified (marine engineering, banking, real estate); long-hold model

Sofina (BE, listed)

Family-controlled investment company

Capital

Larger; global growth/VC and fund exposure; trades at a discount

GBL – Groupe Bruxelles Lambert (BE, listed)

Holding company

Capital; overlaps with Anchor-style listed stakes

Much larger; listed minority stakes plus private assets

Deutsche Beteiligungs AG – DBAG (DE, listed)

Listed PE investor/manager

DACH mid-market deals; capital

Closest listed DACH analogue; fund-management fee income model

Eurazeo (FR, listed)

Listed PE and asset manager

French mid-market deals; capital

Larger; third-party AUM model

Wendel (FR, listed)

Investment holding

Capital

Larger; pivoting to asset management

3i Group (UK, listed)

Listed PE

Capital (benchmark for listed PE)

Much larger; dominated by Action

Mutares (DE, listed)

Special-situations PE

DACH/France deals

Turnaround focus vs Gimv's growth focus

Waterland Private Equity (NL, private)

Buy-and-build PE

Benelux/DACH deals

Direct deal competitor in buy-and-build

NPM Capital (NL, private)

Evergreen investor

Dutch deals

Permanent-capital competitor

Bencis (BE/NL, private)

Mid-market PE

Benelux deals

Direct competitor; previously co-sold Xeikon with Gimv-XL

Ambienta (IT, private)

Sustainability-focused PE

Sustainable Cities deals

Competitor and counterparty (sold Cap Vert to Gimv)

IK Partners, Ardian, Naxicap, Sagard (private)

Pan-European / French mid-market PE

Deals

Larger fund-based competitors; Sagard bought Acceo from Gimv, Naxicap bought Accent Jobs

Peer Comparison FY2025

MetricGimvDBAGEurazeoSofina

Model

Balance-sheet direct PE, sector platforms

Balance sheet plus fund manager

Balance sheet plus large third-party AUM

Family holding, global growth/VC and funds

NAV / equity

EUR 2,105 mio (Jun 2026)

———

Recent annual portfolio return

18.8% annualised (H1 2026)

———

Discount to NAV

≈22% (EUR 44.45 vs EUR 57.2)

———

Dividend yield

≈5.8% on EUR 2.60 run-rate

——

Low

R&D intensity

N/M

N/M

N/M

N/M

Company Snapshot

95

Employees

1980

Founded

Antwerp, Belgium

Headquarters

SWOT Analysis

Strengths

  • Above-target, growth-driven returns: portfolio return of 19.1% (FY2023-24), 19.3% (FY2024-25), 19.1% annualised (FY2025) and 18.8% annualised (H1 2026), vs a 17.5% target; EBITDA growth contributed EUR 196.3 mio of the EUR 198.8 mio H1 2026 portfolio result.
  • Scaled portfolio: EUR 2,407 mio at June 2026 (CAGR ≈13.5% since March 2021), above EUR 2.5 bn including Cap Vert.
  • Strong liquidity: EUR 531.4 mio available at 30 June 2026 (EUR 131.4 mio cash plus EUR 400 mio undrawn RCF), EUR 456.4 mio after the July bond repayment.
  • Low look-through leverage: average portfolio-company leverage 1.8x; companies above 4x leverage represent <5% of portfolio value (Dec 2025).
  • Committed reference shareholder: WorxInvest increased from 28.73% to 37.14% through scrip, rights and market purchases, and co-invests in Anchor and Infravest.
  • Exit discipline: FY2025 exits at a 2.6x money multiple and 12.6% IRR; H1 2026 exits realised EUR 15.5 mio of gains on EUR 42 mio proceeds.
  • Dividend consistency: gross dividend never cut since FY2010-11 (EUR 2.45 → EUR 2.50 → EUR 2.60 annual rate).

Weaknesses

  • Persistent NAV discount: −16.7% (Mar 2024), −26.1% (Mar 2025), −19.0% (Dec 2025), ≈−22% (Aug 2026 price vs June NAV).
  • NAV/share dilution: rights issue at EUR 34.50 vs NAV ≈EUR 55 reduced NAV/share from EUR 55.6 (Sep 2024) to EUR 53.3 (Mar 2025).
  • Cost and LTIP burden: ≈EUR 41 mio of H1 2026 operating costs including EUR 12.1 mio LTIP; LTIP liabilities EUR 57.7 mio.
  • Concentration: top-10 = 50.3% of value; top-5 = ≈30% (Dec 2025).
  • Anchor teething issues: Cegeka (largest exposure category) had a "year of transition" with flat EUR 1.3 bn revenue, restructuring and margin pressure in 2025; Anchor portfolio result was 0.0 in FY2025.
  • Governance optics: Simply Wall St flags fewer than half of directors as independent and limited board refreshment; the reference shareholder controls the chair.
  • Young portfolio, back-ended exits: 38% of value is 2024+ vintage, limiting near-term realisations; H1 2026 exit proceeds were only EUR 42 mio.

Opportunities

  • Cap Vert buy-and-build: fragmented tree/vegetation market; the target integrated >18 businesses since 2021 and has ≈EUR 180 mio revenue.
  • Spineart US expansion: FDA approval of BAGUERA® C (Aug 2026) expands US access, flagged by Gimv as potentially positive for valuation.
  • Anchor pipeline: Anchor described as "ahead of schedule"; listed-minority stakes (Azelis) allow deployment of large tickets at public-market valuations.
  • Industrial recovery: Smart Industries benefiting from improving conditions since late 2025/early 2026 (SI platform value +EUR 53 mio in H1 2026).
  • Digital/AI value creation: new Chief Digital Transformation function and "Combining Intelligence" programme across ≈60 companies with EUR 5 bn combined turnover.
  • Discount narrowing: sustained double-digit NAV growth (+15% annualised in H1 2026) plus a ≈5–6% yield could re-rate the shares.

Threats

  • Macro/geopolitics and energy: Gimv explicitly monitors portfolio exposure to rising energy prices (May 2026).
  • Exit environment: realisations depend on an active M&A market and financing availability (Gimv risk statement).
  • Valuation multiple compression: a FY2022-23-style de-rating produced a −0.1% portfolio return and EUR 59.5 mio net loss.
  • Life Sciences write-downs: LS run-off sleeve (EUR 112 mio) had a −2.2% return in FY2025 including write-downs.
  • Key-person and team risk: departure of the Smart Industries head after 19 years (Sep 2026); LS team restructuring.
  • Weather/consumer sensitivity: adverse weather hit SC companies in early 2026; weak discretionary spending held Consumer to a 4.8% return in FY2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 May 2025FY2024-25 results: record net profit EUR 219 mio; portfolio return 19.3%; NAV/share EUR 53.3; liquidity EUR 668.8 mioSecond consecutive record year
3 Jun 2025Executive share-plan purchases disclosed (FSMA)Management alignment
25 Jun 2025Ordinary and extraordinary AGM; EUR 2.60 optional dividend approvedCapital retention via scrip
22 Jul 2025Investment in Hemink (NL)SC platform expansion
23 Jul 2025Reinvestment in Bugaboo-Joolz combinationConsumer platform; rotation of Joolz into larger asset
23 Jul 2025Optional dividend outcome: 64.2% in shares; EUR 41.8 mio capital increaseCash retained
30 Jul 2025WorxInvest transparency notification: 35.44%Rising control
30 Jul 2025Televic Healthcare Solutions joins Esprit ICTPortfolio carve-out
18 Aug 2025Intec group, Van Severen and Famil join FronntBuy-and-build
28 Aug 2025Partnership with NovicareHealthcare platform
2 Sep 2025Trading updateContinued growth
26 Sep 2025Spineart CHF 25 mio capital increaseMedtech growth funding
8 Oct 2025Complement Therapeutics FDA IND clearanceLS milestone
22 Oct 2025ImCheck exit to IpsenRealised LS gain
31 Oct 2025EPA proposed registration for Biotalys' EVOCALS milestone
5 Nov 2025Investment in Quality GuardNew Consumer platform company
20 Nov 2025H1 FY2025 results: portfolio EUR 2 bn; NAV/share EUR 53.9Growth acceleration
27 Nov 2025CNP joins Equine Care GroupCo-investor added
2 Dec 2025US EPA approval for EVOCALS milestone
5 Dec 2025Cegeka strengthens its boardAnchor governance reset
Jan 2026LS portfolio rounds: Mediar USD 76 mio, Kinaset USD 103 mio; Kivu Phase 1 first dosing; Complement FDA Fast TrackLS value support
16 Jan 2026Majority of ALT Technologies sold to CCL IndustriesExit
20 Jan 2026Gimv leads EUR 51 mio Exciva Series BLast major LS lead
26 Jan 2026Discontinuation of new Life Sciences investments; ExCo to be reviewedStrategic refocus
19 Feb 2026FY2025 (9m) results: net profit EUR 173.3 mio; NAV/share EUR 55.1; EUR 466 mio investedRecord investment pace
Q1 2026RCF renegotiated and doubled to EUR 400 mioLiquidity
Q1 2026Cegeka reports stable 2025 revenue of EUR 1.3 bn; new CEO Koen DeryckereAnchor transition
30 Mar 2026FY2025 annual report publishedFiling
30 Apr 2026Gimv Anchor acquires 5% of AzelisSecond Anchor holding
27 May 2026Q1 2026 trading update: NAV/share EUR 56.7 (unaudited); liquidity EUR 600 mio; energy-price exposure monitoredSteady progress
27 May 2026AGM approves EUR 1.95 cash dividend (5.2% annualised yield at 26 May close)Shareholder return
3 Jun 2026Dividend paid—
25 Jun 2026Agreement to acquire Groupe Cap Vert from AmbientaTop-10 holding; French expansion
30 Jun 2026Sale of AlpenBlu Clinics to Impact HealthcareExit
5 Jul 2026EUR 75 mio bond repayment; outstanding EUR 275 mioDeleveraging
11 Aug 2026Metis Group agrees to acquire majority of EPACSI buy-and-build
Aug 2026Spineart BAGUERA® C FDA approval (1 and 2 levels)Potential valuation uplift
Aug 2026Sale of MVZ HoldingExit, no NAV impact
3 Sep 2026H1 FY2026 results: NAV/share EUR 57.2; portfolio EUR 2.4 bn; net profit EUR 148.4 mioAbove-target returns
3 Sep 2026Creation of Chief Digital Transformation ExCo role; Tom Van de Voorde (Head of SI) to leaveLeadership change
Sep 2026Expected closing of Cap Vert–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

1 chart
Revenue by Segment (EUR): Total portfolio rose from EUR 2,121 in Dec2025 to EUR 2,407 in Jun2026.
Gimv NV — Revenue by Segment (EUR)
Series (EUR)Dec2025Jun2026
Total portfolio2,1212,407
Consumer369412
Healthcare503504
Smart Industries454507
Sustainable Cities418480
Anchor165277
Life Sciences109112
Infra and other103115

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.